Journal article
Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance
K Lindemann, B Gao, C Mapagu, S Fereday, C Emmanuel, K Alsop, N Traficante, PR Harnett, DDL Bowtell, A deFazio
Gynecologic Oncology | ACADEMIC PRESS INC ELSEVIER SCIENCE | Published : 2018
Abstract
Objective: The aim of this study was to compare response rates and survival in women with “platinum resistant” epithelial ovarian cancer (EOC) who received further platinum-based or non‑platinum chemotherapy for treatment at first relapse. Methods: Patients with high-grade EOC (including fallopian tube and peritoneal cancer) of all histologies recruited to the Australian Ovarian Cancer Study (AOCS) and treated with platinum-based primary chemotherapy were included. Response to second-line chemotherapy, overall survival (OS) and survival after treatment for first progression (OS2) were determined in all histologies and separately in women with high-grade serous tumors. Results: Of the 341 pat..
View full abstractGrants
Awarded by Medical Research and Materiel Command
Funding Acknowledgements
The Australian Ovarian Cancer Study was supported by the U.S. Army Medical Research and Materiel Command under DAMD17-01-1-0729, The Cancer Council Victoria, Queensland Cancer Fund, The Cancer Council New South Wales, The Cancer Council South Australia, The Cancer Foundation of Western Australia, The Cancer Council Tasmania and the National Health and Medical Research Council of Australia (NHMRC; ID400413, ID40028). The AOCS gratefully acknowledges additional support from S. Boldeman, the Agar family, Ovarian Cancer Action (UK), Ovarian Cancer Australia and the Peter MacCallum Foundation. AdeF is funded by the University of Sydney Cancer Research Fund and the Cancer Institute NSW through the Sydney-West Translational Cancer Research Centre.